Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Biogen Pharmachem Industries Ltd has touched a new 52-week low of Rs.0.63 today, marking a significant decline in its stock price amid broader market pressures and company-specific factors. This fresh low reflects ongoing challenges faced by the company within the Non Banking Financial Company (NBFC) sector, as it continues to trade below all key moving averages and underperforms its sector peers.

Biogen Pharmachem Industries Ltd has reached a new 52-week low of Rs.0.64, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures. This latest low reflects ongoing concerns about the company’s financial health and valuation metrics within the Non Banking Financial Company (NBFC) sector.

Biogen Pharmachem Industries Ltd has touched a new 52-week low of Rs.0.65 today, marking a significant decline in its share price amid broader market pressures and company-specific financial concerns.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 19 January 2026, providing investors with the latest view of the stock’s position in the market.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 07 January 2026, providing investors with the most up-to-date view of its fundamentals, valuation, financial trend, and technical standing.

Biogen Pharmachem Industries Ltd has declined to a fresh 52-week low of Rs.0.68, marking a significant drop in its share price amid a broader market environment where the Sensex continues to show strength. This new low reflects ongoing pressures on the stock, which has underperformed its sector and the broader market over the past year.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 25 December 2025, providing an up-to-date view of the stock’s position in the market.

Biogen Pharmachem Industries has reached a new 52-week low of Rs.0.7, marking a significant decline in its stock price amid subdued financial performance and persistent downward momentum over recent sessions.

Biogen Pharmachem Industries has reached a new 52-week low, with its stock price touching Rs.0.71 today. This marks a significant milestone as the stock continues to trade below all key moving averages amid a broader market downturn.

Biogen Pharma, a microcap player in the Non Banking Financial Company (NBFC) sector, has recently undergone a revision in its evaluation metrics reflecting a more cautious market assessment. This shift comes amid persistent operational challenges and subdued financial trends, impacting investor sentiment and stock performance.

Biogen Pharmachem Industries has reached a new 52-week low, with its share price touching Rs.0.72 today. This marks a significant decline from its 52-week high of Rs.1.29, reflecting ongoing pressures within the company amid a broader market environment where the Sensex is trading near its yearly peak.

Biogen Pharmachem Industries has reached a new 52-week low, with its share price touching Rs.0.73 today. This marks a significant decline over the past year, reflecting ongoing pressures within the company and the broader market environment.

Biogen Pharmachem Industries has reached a new 52-week low of Rs.0.74, marking a significant decline in its stock price amid broader market gains. The stock has underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures within the company’s financial performance.

Biogen Pharmachem Industries, a microcap in the NBFC sector, reported a flat performance for the quarter ending September 2025, with a decline in financial metrics. Despite a higher profit after tax of Rs 0.85 crore over six months, the company faces significant challenges, including low quarterly profit figures and a substantial stock decline.